Trial reportHead & face medicine2025
Application value of indocyanine green lymphography in the management of stage I/IIA microcystic lymphatic malformation of the tongue.
Trial report in Head & face medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06755905 (Application Value of Indocyanine Green Lymphography in Management of Microcystic Lymphatic Malformation of the Tongue), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application Value of Indocyanine Green Lymphography in Management of Microcystic Lymphatic Malformation of the Tongue
Who cites it
2 citing papers in PubMed.
- Study on the Application of Indocyanine Green Lymphography in the Management of Microcystic Lymphatic Malformation: A Randomized Clinical Trial.Children (Basel, Switzerland) · 2026Article
- Clinical Applications of Indocyanine Green Fluorescence Imaging in Vascular Malformations: A Systematic Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study aims to investigate whether indocyanine green lymphography (ICGL) facilitates the effectiveness and accuracy of current management of lingual microcystic lymphatic malformation (mLM).
methodsThis retrospective included patients under 18 years old with mLM of the tongue staged I or IIA, who underwent ICGL-aided surgical resection and sclerotherapy (ICGL group) or only surgical resection and sclerotherapy (non-ICGL group) between January 2019 and June 2024. The peri- and postoperative parameters of safety and feasibility were compared between two groups.
resultsA total of 42 patients were included, 19 of whom received ICGL-guidance and the other 23 were in non-ICGL group. The comparison of baseline data between the two groups revealed no significant difference. Compared to the non-ICGL group, the ICGL group demonstrated superior efficacy (P = 0.017) and required fewer subsequent treatment sessions (P = 0.027), but had longer operative duration (P = 0.001). No significant differences were observed in terms of postoperative complications, length of hospital-stay, and follow-up period.
conclusionsICGL was associated with improved postoperative outcomes and less subsequent treatment. This technique may provide rational guidance with promising clinical prospects for management of mLM of the tongue. TRAIL REGISTRATION: This study was retrospectively registered on clinicaltrials.gov: NCT06755905, date of registration: January 20, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.